Sep 2026
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
Allogeneic CAR T cells could overcome limitations of autologous therapies but are limited by immune rejection. We evaluated 11 patients with large B‑cell lymphoma treated with a single lot of cemacabtagene ansegedleucel (cema-cel), an allogeneic anti‑CD19 CAR T product. Despite receiving identical infusion products, pa...
A. Jallouk, Zhong-Qi Ge, V. Kaimal et al.
· Cancer Discovery · 0 citations